-
Runway in sight for a 'Goldilocks' soft landing for US economy, insurers believe
13 March 2024US insurers and their asset managers are hopeful a recession has been avoided, and though "landmines" persist, even areas suffering negative headlines such as real estate should deliver opportunities
-
Looking for a home for natural capital in insurers' investment portfolios
12 March 2024Understanding new risks, a lack of asset managers able to service these types of investments at scale, and the question of where to include natural capital in the SAA are the hurdles insurers need to overcome, Danielle Brassel, director of responsible investment at Zurich Insurance Group, explains
-
Chart of the Week - How IMAs could spell out the future of PE ownership of insurers
23 February 2024Fee rates, and other T&Cs in the IMAs of PE houses and the consolidators they own, may attract (unwanted) regulatory attention
-
Fitch says PE ownership not necessarily credit-negative for insurers
15 February 2024Ratings agency looks at insurers' investment strategy riskiness among other facets for credit assessments
-
Zurich Insurance appoints chief sustainability officer
14 February 2024Linda Freiner is promoted to role after nearly seven years at the company
-
Achmea not ruling out offloading life and pensions business - worth €21.9bn of general account
12 February 2024Deal would involve group transferring up to 60% of its general account assets
-
2024 a vintage year for real estate, Zurich predicts
09 February 2024Even if environment remains fragile
-
Chart of the Week - As a €21bn deal is scuppered by BaFin, have PE owners run out of road for life book sales?
02 February 2024German regulator's refusal to Zurich and Viridium seems bad news for insurers owned by PE
-
German backbook deals and run-offs - a €150bn asset industry since 2014
01 February 2024Moody's examined 14 deals, completed, pending and scuttled
-
Comment - BaFin holds cards (close to its chest) in future of German life-book consolidation
01 February 2024PE part-ownership of Viridium seems to have informed regulator's rejection of Zurich deal